Liothyronine Sodium (T3) is the L-isomer of triiodothyronine — a biologically active thyroid hormone. It is often studied for its ability to increase metabolic rate, enhance cellular energy output, and accelerate lipid metabolism. In research models, T3 is valued for exploring thyroid hormone dynamics and their role in weight regulation and energy expenditure.

Background

Liothyronine Sodium (T3) is pharmacologically distinct from Levothyroxine (T4). While T4 (Eltroxin) is slow-acting with a long plasma half-life (~11 days), T3 demonstrates rapid onset and short duration, making it more practical for studies requiring fast response cycles. Its high bioavailability (~95%) and short half-life (~12 hours) allow researchers to track immediate thyroidal effects and recovery after cessation.

In contrast to Eltroxin, which can suppress natural thyroid function for up to six weeks post-cessation, Liothyronine clears within 24–36 hours — enabling faster normalization and greater dosage flexibility in research conditions.

Observed Effects (Research Context)

• Increased basal metabolic rate (BMR) and caloric turnover
• Enhanced fat oxidation and lipolytic activity
• Improved thermogenic response and energy expenditure
• Short plasma half-life allowing rapid response tracking

Commonly Reported Side Effects

• Transient increases in heart rate, perspiration, or nervousness
• Occasional irritability or mild tremors in sensitive subjects
• Temporary digestive changes or elevated core temperature
• Symptoms typically self-resolve within 24 hours post-administration

Dosage & Cycle Guidance (Research Use)

• Typical study range: 20–100 mcg per day
• Initial phase: Begin with 25 mcg/day and increase by 25 mcg every 3–4 days
• Cycle duration: 4–6 weeks typical maximum
• Tapering protocol: Reduce by 10–25 mcg every 3–4 days at cycle end

This gradual increase and reduction model helps simulate thyroid adaptation and recovery dynamics, allowing the endocrine system to re-stabilize naturally at the end of a test period.

Additional Cautions

• Avoid stacking with high-stimulant agents such as Ephedrine or Clenbuterol without monitoring total heart rate response
• Overstimulation may reduce aerobic capacity and endurance performance
• Monitor resting heart rate and temperature to track metabolic load

What's in the Box

• 56 tablets per box (4 × 14 blister packs)
• Each tablet contains 50 mcg Liothyronine Sodium (T3)

Storage & Handling

• Store below 25 °C in a dry, light-protected environment
• Keep sealed until use to preserve stability and potency

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals ensures accurate compound identity and potency verification using HPLC and spectrophotometric assays. Each production batch undergoes quantitative purity testing and visual inspection for consistent research reliability.

For research, analytical, and educational purposes only. Not for human or veterinary consumption. No therapeutic claims are made or implied. Buyer assumes responsibility for lawful handling and compliance with all regulations.